Vogenx is a clinical-stage biopharmaceutical company developing mizagliflozin for metabolic and gastrointestinal diseases. Mizagliflozin is an oral, selective SGLT1 inhibitor that acts locally in the gut to reduce and delay glucose absorption. By blocking glucose uptake in the small intestine, the drug suppresses the excessive insulin and hormone secretions that cause post-bariatric hypoglycemia (PBH), a complication of weight-loss surgery which leads to dangerous low blood sugar episodes. Vogenx is currently preparing to initiate a Phase 2b clinical trial for PBH in 2026. The company also plans to develop mizagliflozin for gastroparesis and GIP-dependent Cushing's Syndrome, alongside a preclinical candidate, VGX-2857, for weight maintenance. Vogenx is a pre-revenue company that funds operations through equity and debt financing. The company holds exclusive worldwide rights to mizagliflozin, excluding Japan, Korea, and Taiwan, through a license agreement with Kissei Pharmaceutical that requires future milestone and royalty payments. Vogenx intends to commercialize its products through a focused direct sales force or through strategic partnerships after securing regulatory approvals. The company’s strategy focuses on treating conditions where its gut-targeted mechanism addresses the root cause of glucose-related hormonal imbalances.